Mon, Sep 22, 2014, 8:54 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Endo International plc Message Board

  • EquityMaestro EquityMaestro Jun 17, 2005 12:00 AM Flag

    I don't get it.....


    I bought ENDP a couple of weeks back at about $24/share. My investment thesis was partially based on momentum and partially based on the fact that this is a great long-term business given the aging population. When IVAX and Purdue announced the "authorzed generic" version of OxyContin, I crapped my pants thinking that ENDP would drop into the $21-22 range due to the fact that they no longer have a monopoly on the marketing of generic OxyContin for the next 180 days. However, to my delight, the stock is actually up about $.60 since that IVAX news release. I'm happy with the price increase, but am also puzzled as to why ENDP hasn't fallen over the last couple of weeks due to this loss of exclusivity.

    Any experts have an educated opinion on this issue? Cheerleading investment rookies need not reply.

    The Maestro

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Bear Stearns have note out saying Oxycontin may add.43c a share this year. The gen Duralgesic patch should be approved "any day". Most analysts had Endo at a discount because of the uncertainty surrounding Oxyc and the appeal. After having had a period with delays (appeal, oxymorphine) Endo seems to be on the right track. Great pipeline, good execution. I don't think Ivax will have that much impact. After all, Endo is the "King of Pain"

66.16-1.54(-2.27%)Sep 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.